Decoy Therapeutics Inc. Debt Securities, Available-for-sale, Amortized Cost
Decoy Therapeutics Inc. (DCOY) had Debt Securities, Available-for-sale, Amortized Cost of $14.13 million as of 2017-12-31, per its 10-K filed 2019-03-06.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2019-03-06
- 2017-12-31: Debt Securities, Available-for-sale, Amortized Cost $14.13M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2017-12-31 | $14.13M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |